| [1] |
Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives [J]. Lancet, 2013, 382(9888): 260-272.
|
| [2] |
Einhorn LM, Zhan M, Hsu VD, et al. The frequency of hyperkalemia and its significance in chronic kidney disease [J]. Arch Intern Med, 2009, 169(12): 1156-1162.
|
| [3] |
Weinberg JM, Appel LJ, Bakris G, et al. Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy [J]. Arch Intern Med, 2009, 169(17): 1587-1594.
|
| [4] |
Seliger SL. Hyperkalemia in patients with chronic renal failure [J]. Nephrol Dial Transplant, 2019, 34(Suppl 3): iii12-iii18.
|
| [5] |
Belmar Vega L, Galabia ER, Bada da Silva J, et al. Epidemiology of hyperkalemia in chronic kidney disease [J]. Nefrologia, 2019, 39(3): 277-286.
|
| [6] |
Palmer BF, Clegg DJ. Physiology and pathophysiology of potassium homeostasis [J]. Adv Physiol Educ, 2016, 40(4): 480-490.
|
| [7] |
Coutrot M, Dépret F, Legrand M. Tailoring treatment of hyperkalemia [J]. Nephrol Dial Transplant, 2019, 34(Suppl 3): iii62-iii68.
|
| [8] |
Labriola L, Jadoul M. Sodium polystyrene sulfonate: still news after 60 years on the market [J]. Nephrol Dial Transplant, 2020, 35(9): 1455-1458.
|
| [9] |
Noel JA, Bota SE, Petrcich W, et al. Risk of hospitalization for serious adverse gastrointestinal events associated with sodium polystyrene sulfonate use in patients of advanced age [J]. JAMA Intern Med, 2019, 179(8): 1025-1033.
|
| [10] |
Watson MA, Baker TP, Nguyen A, et al. Association of prescription of oral sodium polystyrene sulfonate with sorbitol in an inpatient setting with colonic necrosis: a retrospective cohort study [J]. Am J Kidney Dis, 2012, 60(3): 409-416.
|
| [11] |
Bakris GL, Pitt B, Weir MR, et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial [J]. JAMA, 2015, 314(2): 151-161.
|
| [12] |
李晓，徐钢，林洪丽，等. 聚苯乙烯磺酸钙治疗慢性肾脏病高钾血症患者的多中心临床研究[J]. 中华肾脏病杂志，2013, 29(6): 419-422.
|
| [13] |
Yu MY, Yeo JH, Park JS, et al. Long-term efficacy of oral calcium polystyrene sulfonate for hyperkalemia in CKD patients [J]. PLoS One, 2017, 12(3): e0173542.
|
| [14] |
Keng LT, Tsou PH. Unusual ileus due to calcium polystyrene sulfonate [J]. Postgrad Med J, 2016, 92(1091): 563.
|
| [15] |
Ribeiro H, Pereira E, Banhudo A. Colonic necrosis induced by calcium polystyrene sulfonate [J]. GE Port J Gastroenterol, 2018, 25(4): 205-207.
|
| [16] |
Li L, Harrison SD, Cope MJ, et al. Mechanism of action and pharmacology of patiromer, a nonabsorbed cross-linked polymer that lowers serum potassium concentration in patients with hyperkalemia [J]. J Cardiovasc Pharmacol Ther, 2016, 21(5): 456-465.
|
| [17] |
Bushinsky DA, Spiegel DM, Gross C, et al. Effect of patiromer on urinary ion excretion in healthy adults [J]. Clin J Am Soc Nephrol, 2016, 11(10): 1769-1776.
|
| [18] |
Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors [J]. N Engl J Med, 2015, 372(3): 211-221.
|
| [19] |
Bushinsky DA, Williams GH, Pitt B, et al. Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia [J]. Kidney Int, 2015, 88(6): 1427-1433.
|
| [20] |
Agarwal R, Rossignol P, Romero A, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial [J]. Lancet, 2019, 394(10208): 1540-1550.
|
| [21] |
Ganesan C, Pao AC. Spironolactone plus patiromer: proceed with caution [J]. Lancet, 2019, 394(10208): 1486-1488.
|
| [22] |
Packham DK, Kosiborod M. Pharmacodynamics and pharmacokinetics of sodium zirconium cyclosilicate [ZS-9] in the treatment of hyperkalemia [J]. Expert Opin Drug Metab Toxicol, 2016, 12(5): 567-573.
|
| [23] |
Stavros F, Yang A, Leon A, et al. Characterization of structure and function of ZS-9, a K+ selective ion trap [J]. PLoS One, 2014, 9(12): e114686.
|
| [24] |
Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial [J]. JAMA, 2014, 312(21): 2223-2233.
|
| [25] |
Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia [J]. N Engl J Med, 2015, 372(3): 222-231.
|
| [26] |
白婵，尚进，康冬，等. 环硅酸锆钠散对慢性肾脏病高钾血症患者短期降钾效果的临床观察[J]. 中华医学杂志，2020, 100(38): 2997-3000.
|
| [27] |
Nilsson E, Gasparini A, Arnlov J, et al. Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system [J]. Int J Cardiol, 2017, 245: 277-284.
|
| [28] |
Spinowitz BS, Fishbane S, Pergola PE, et al. Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month phase 3 study [J]. Clin J Am Soc Nephrol, 2019, 14(6): 798-809.
|
| [29] |
Roger SD, Lavin PT, Lerma EV, et al. Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, phase 3 study [J]. Nephrol Dial Transplant, 2021, 36(1): 137-150.
|
| [30] |
Fishbane S, Ford M, Fukagawa M, et al. A phase 3b, randomized, double-blind, placebo-controlled study of sodium zirconium cyclosilicate for reducing the incidence of predialysis hyperkalemia [J]. J Am Soc Nephrol, 2019, 30(9): 1723-1733.
|
| [31] |
中华医学会肾脏病学分会专家组. 中国慢性肾脏病患者血钾管理实践专家共识[J].中华肾脏病杂志，2020, 36(10): 781-792.
|
| [32] |
Davidson JP, King AJ, Kumaraswamy P, et al. Evaluation of the pharmacodynamic effects of the potassium binder RDX7675 in mice [J]. J Cardiovasc Pharmacol Ther, 2018, 23(3): 244-253.
|
| [33] |
Pitt B, Zann V, Roe C, et al. An evaluation of the pharmacodynamics, safety, and tolerability of the potassium binder RDX7675 [J]. J Clin Pharmacol, 2018, 58(8): 1035-1043.
|
| [34] |
Zann V, McDermott J, Jacobs JW, et al. Palatability and physical properties of potassium-binding resin RDX7675: comparison with sodium polystyrene sulfonate [J]. Drug Des Devel Ther, 2017, 11: 2663-2673.
|
| [35] |
Yu JG, Fan BS, Guo JM, et al. Anisodamine ameliorates hyperkalemia during crush syndrome through estradiol-induced enhancement of insulin sensitivity [J]. Front Pharmacol, 2019, 10: 1444.
|